PathoLase, Inc. Launches PinPointe(TM) FootLaser(TM)

Leading Podiatrists Now Treating Patients in Several Major Markets
CHICO, Calif.--(Business Wire)--
PathoLase, Inc., an emerging leader in the medical technology
industry, reported today that a select group of leading podiatrists in
several markets in the US are now treating patients who suffer from
toenail fungus (Onychomycosis) with its ground breaking laser
technology. Using PathoLase's patented PinPointe FootLaser system,
podiatrists in Sacramento, San Jose, Salt Lake City and Belleville,
New Jersey are open for business treating their patients' toenail
fungus.

"The PinPointe FootLaser system is a technological marvel," said
Michael Uro, DPM from Sacramento. "My patients love that fact that I
can treat them safely and quickly with no drugs, no anesthesia, no
pain and no side effects."

Led by medical laser pioneer, David Harris, PhD, Director of
Science & Regulatory Affairs for PathoLase, the company recently
brought its patented laser technology to market after several years of
research and development. With over 20 years of medical laser
development to his credit, Dr. Harris has overseen the development of
this groundbreaking technology.

"With an estimated 40 million people in the US suffering from
toenail fungus infections, PathoLase is committed to making our
PinPointe FootLaser system available to as many sufferers as quickly
as we can throughout the US," noted John Strisower, CEO of PathoLase.

Commented Brian McDowell, DPM also from Sacramento, "Response to
our initial advertising announcing the availability of this wonderful
technology has been overwhelming. Patients are thrilled that the
medical technology industry has finally developed a sophisticated
laser system that kills the pathogens that cause toenail fungus
quickly and efficiently. I have had patients call their friends and
family from my examining room encouraging them to make their own
appointments immediately. We've never seen a public response like this
to new drugs or ointments that treat toenail fungus. Nor have we ever
had a solution with PinPointe's high rate of success to offer our
patients."

PathoLase is the only medical laser technology currently available
in the marketplace that kills the pathogens that cause toenail fungus.
The company expects to introduce its leading edge laser technology
into another 20 major markets in the next several months.

About PathoLase

Founded in 2004, PathoLase, Inc. is a privately held emerging
medical technology company with headquarters in Northern California.
PathoLase has assembled a world-class group of top scientists,
academic thought leaders and leading practitioners from around the US
and Canada to develop and bring to market a new generation of laser
technology solutions that address a series of medical issues, from
toenail fungus and periodontal disease to more serious life
threatening problems, such as blood borne and respiratory infections.

PathoLase's first laser solution now available in the marketplace
addresses the pathogens that cause toenail fungus (Onychomycosis), an
infection that afflicts an estimated 40 million people in the US
alone. With Series A private equity capital recently secured from
Nexus Medical Partners, PathoLase is rapidly placing its patented
technology in the hands of leading podiatrists around the country.

For PathoLase, Inc.
Bill Bradley, 916-658-0144
bill@perrycom.com

Copyright Business Wire 2008